Ali Momeni1, Ali Hajigholami2, Shohreh Geshnizjani3, Soleiman Kheiri4. 1. Nephrologist, Division of Nephrology, Department of Internal Medicine, Shahrekord University of Medical Sciences , Shahrekord, Iran . 2. Haematologist, Division of Hematology, Department of Internal Medicine, Shahrekord University of Medical Sciences , Shahrekord, Iran . 3. Internist, Division of Nephrology, Department of Internal Medicine, Shahrekord University of Medical Sciences , Shahrekord, Iran . 4. Biostatistician, Clinical Biochemistry Research Center, Shahrekord University of Medical Sciences , Shahrekord, Iran .
Abstract
BACKGROUND: Reno-protective effect of Silymarin was studied in some studies mainly on rats. In some of these studies, Silymarin was shown to have positive effects on preventing or decreasing severity of Cisplatin nephrotoxicity. OBJECTIVE: The aim of this study was to evaluate the protective effect of Silymarin on Cisplatin nephrotoxicity in adult patients with malignancy. MATERIALS AND METHODS: In this clinical trial study, 60 patients with malignancy, candidate of Cisplatin treatment were randomly enrolled in two equal groups. In patients of case group, Silymarin tablet 140 mg/bid was administrated seven days before Cisplatin administration together with Cisplatin, and in control group, Cisplatin was prescribed. Blood Urea Nitrogen (BUN) and serum Creatinine (Cr) were checked at the same day and 3 and 7 days after administration of Cisplatin. RESULTS: Mean age of the patients in case and control groups were 51.1±14.3 y and 51.1±13.7 y respectively (p=0.99). There was no significant difference based on BUN and serum Cr in the beginning of study and three days after administration of Cisplatin in two groups of patients; however, after two weeks, BUN and serum Cr were significantly lower in the case group compared to the control group. Also, in the case group, BUN and serum Cr decreased and in the control group, they increased after two weeks after Cisplatin administration. CONCLUSION: This study showed that Silymarin can decrease Cisplatin nephrotoxicity, so because of safety profile and minor adverse effect of Silymarin, we can use it as prophylaxis against Cisplatin nephrotoxicity in various Cisplatin-contained chemotherapy regimens.
RCT Entities:
BACKGROUND: Reno-protective effect of Silymarin was studied in some studies mainly on rats. In some of these studies, Silymarin was shown to have positive effects on preventing or decreasing severity of Cisplatinnephrotoxicity. OBJECTIVE: The aim of this study was to evaluate the protective effect of Silymarin on Cisplatinnephrotoxicity in adult patients with malignancy. MATERIALS AND METHODS: In this clinical trial study, 60 patients with malignancy, candidate of Cisplatin treatment were randomly enrolled in two equal groups. In patients of case group, Silymarin tablet 140 mg/bid was administrated seven days before Cisplatin administration together with Cisplatin, and in control group, Cisplatin was prescribed. Blood UreaNitrogen (BUN) and serum Creatinine (Cr) were checked at the same day and 3 and 7 days after administration of Cisplatin. RESULTS: Mean age of the patients in case and control groups were 51.1±14.3 y and 51.1±13.7 y respectively (p=0.99). There was no significant difference based on BUN and serum Cr in the beginning of study and three days after administration of Cisplatin in two groups of patients; however, after two weeks, BUN and serum Cr were significantly lower in the case group compared to the control group. Also, in the case group, BUN and serum Cr decreased and in the control group, they increased after two weeks after Cisplatin administration. CONCLUSION: This study showed that Silymarin can decrease Cisplatinnephrotoxicity, so because of safety profile and minor adverse effect of Silymarin, we can use it as prophylaxis against Cisplatinnephrotoxicity in various Cisplatin-contained chemotherapy regimens.
Authors: D Portilla; S Li; K K Nagothu; J Megyesi; B Kaissling; L Schnackenberg; R L Safirstein; R D Beger Journal: Kidney Int Date: 2006-05-03 Impact factor: 10.612
Authors: Zhiming Wen; Todd E Dumas; Sarah J Schrieber; Roy L Hawke; Michael W Fried; Philip C Smith Journal: Drug Metab Dispos Date: 2007-10-03 Impact factor: 3.922
Authors: W Siegert; J Beyer; I Strohscheer; H Baurmann; H Oettle; J Zingsem; R Zimmermann; C Bokemeyer; H J Schmoll; D Huhn Journal: J Clin Oncol Date: 1994-06 Impact factor: 44.544
Authors: Alfredo G Casanova; María Teresa Hernández-Sánchez; Francisco J López-Hernández; Carlos Martínez-Salgado; Marta Prieto; Laura Vicente-Vicente; Ana Isabel Morales Journal: Eur J Clin Pharmacol Date: 2019-11-01 Impact factor: 2.953